Hologic — Q4 2023 Earnings Presentation
37 slides from Hologic's earnings presentation, Nov 9, 2023
Slide 1: Purpose Driven. Results Driven.
Purpose Driven. Results Driven. November 2023 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking information that involves risks and uncertainties, including statements about the Company’s plans, objectives, expectations and intentions. Such statements include, without limitation: financial or other information based upon or other
Slide 3: Non-GAAP Financial Measures
Non-GAAP Financial Measures The Company has presented the following non-GAAP financial measures in this presentation: constant currency revenues; organic revenues; non-GAAP gross margin; non-GAAP operating expenses; non-GAAP operating margin; non-GAAP effective tax rate; non-GAAP net income; non-GAA
Slide 4: Presentation Outline
Presentation Outline Introduction Purpose Driven Results Driven Conclusion and Financials 4
Slide 5: Investment Thesis
Investment Thesis • Purpose Driven, Results Driven • Commitment to purpose supercharges engagement and amplifies strength • Transformation into a much stronger Company than pre-pandemic ○ More diverse, recurring revenue ○ More long-term growth opportunities ○ More global ○ With stronger base busines
Slide 6: Presentation Outline
Presentation Outline Introduction Purpose Driven Results Driven Conclusion 6
Slide 7: An Unparalleled Commitment to Women's Health
An Unparalleled Commitment to Women's Health 7
Slide 8: ESG Focus: Making a Unique Difference in the World
ESG Focus: Making a Unique Difference in the World • Strong financial results enable us to live into our Purpose, Passion and Promise more fully than ever before • Driving meaningful change with the Hologic Global Women’s Health Index, Project Health Equality and our Global Access Initiative • Focus
Slide 9: Our Purpose Creates A Unique Strength
Our Purpose Creates A Unique Strength Together, we achieve MORE! 9
Slide 10: Elevating Global Women's Health…
Elevating Global Women's Health… …Through important social initiatives including: Hologic Global Women’s Health Index Project Health Equality Global Access Initiative 10
Slide 11: Elevating Hologic's Company Profile…
Elevating Hologic’s Company Profile… …By engaging world leaders, scoring big at the Super Bowl and partnering with the WTA — a global effort with global reach World Economic Forum Mary J. Blige & the Super Bowl Women’s Tennis Association 11
Slide 12: Culture Creates Competitive Advantage
Culture Creates Competitive Advantage Purpose + Results = World Class Engagement Engagement underpins our recognition as a highly Purpose underpins exceptional engagement ranked Top Workplace Stellar Engagement per Gallup Q12 Survey 2022 recognition as a Top Workplace at two of our largest employee
Slide 13: Presentation Outline
Presentation Outline Introduction Purpose Driven Results Driven Conclusion and Financials 13
Slide 14: Hologic Overview
Hologic Overview • Revenue of $4,030 million in fiscal 2023 By Division By Type By Geography Surgical Service 15% and Other INTL 19% 24% Diagnostics Capital 47% Consumables Breast and 18% Skeletal 63% 38% US 76% Note: Percentages in pie charts are for FY23. 14
Slide 15: Strong Fiscal 2023 with Base Businesses Driving Growth…
Strong Fiscal 2023 with Base Businesses Driving Growth… Total Revenue* 46.5% $6,000 $5,632 -12.3% $4,863 $5,000 12.1% -16.3% $2,160 5.7% $1,431 $4,030 $4,000 4.3% $3,776 $248 8.3% $3,367 $3,218 9.9% 5.4% $3,059 $929 $3,000 0.4% $2,000 ** $1,000 $2,511 $2,705 $2,833 $2,851 $2,879 $3,052 $2,782 $3,473
Slide 16: …And Deliver Robust Profitability
…And Deliver Robust Profitability Non-GAAP EPS* $9.00 111.3% $8.00 $7.00 -28.4%** $6.00 $5.00 63.8% -34.2% $4.00 $3.00 9.9% 9.0% 17.4% 3.6% $2.00 14.4% -2.7% $1.00 $1.46 $1.67 $1.96 $2.03 $2.23 $2.43 $3.98 $8.41 $6.02 $3.96 $0.00 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 *Non-GAAP EPS as pre
Slide 17: Generated $5.9 Billion in FCF over the Past 4 Years
Generated $5.9 Billion in FCF over the Past 4 Years $3.5 Billion Deployed Since FY’20 M&A Accelerates Growth • Redeployed FCF* to drive growth across • 6 deals across each division the board ○ Diagnostics • Over $1.4 billion on M&A** – Biotheranostics, Diagenode, Mobidiag ○ Breast Health • Over $2.1
Slide 18: Strong Q4 2023 Results
Strong Q4 2023 Results Q4’22 Q4’23 Revenue Change (CC) Revenue Diagnostics $416.4 $520.9 (20.6%) Organic Diagnostics $361.4 $325.4 10.2% excluding COVID Organic Molecular Diagnostics excluding $246.2 $212.6 15.0% COVID Breast Health $352.8 $275.1 27.4% GYN Surgical $148.0 $133.3 10.6% Skeletal Healt
Slide 19: Diagnostics Powered by Molecular…
Diagnostics Powered by Molecular… Global Diagnostics* Revenue • Molecular Diagnostics drives Growth: $1,479 ○ +3,260 Panther instruments globally $1,321 ○ Menu adoption and utilization drive $1,029 long-term growth $998 $846 Upside from COVID testing Millions ○ $557 • Steadfast leadership in Cytolog
Slide 20: …With Improving Utilization Post-COVID…
…With Improving Utilization Post-COVID… • Panther non-COVID utilization gaining traction • Global ex. COVID Panther pull through continues to increase • 15.0% constant currency organic Molecular Diagnostics revenue growth ex. COVID in Q4’23 Note: Organic revenue excludes the divested Blood Screening
Slide 21: …And a Broad Menu with More on the Way
…And a Broad Menu with More on the Way FDA Approved Assays on Panther* • Menu in development for FDA 21 approval: ○ GI ○ EBV and BKV ○ C. Difficile ○ M. gen resistance ○ Chlamydia trachomatis 4 ○ Neisseria gonorrhoeae 2014 Q4'23 * Includes both Panther and Panther Fusion. 21
Slide 22: Breast Health Recovery Continues…
Breast Health Recovery Continues… • A more diverse and recurring business Breast Health Revenue • 2023 recovery in Mammography $1,600 $1,400 ○ Breast Health constant currency revenue up $1,200 42% 27.4% in Q4’23 $1,000 $800 • Interventional and International drive growth 38% 22% $600 17% • IMV Servi
Slide 23: …with Leadership Across the Continuum of Care
…with Leadership Across the Continuum of Care ARTIFICIAL INTELLIGENCE & ANALYTICS 23
Slide 24: Robust Surgical Growth
Robust Surgical Growth Global Surgical Revenue* • Stability in NovaSure $600 $522 • Continued strength in core MyoSure $437 • Underappreciated contribution from Fluent Fluid Management Millions • Strong growth in Laparoscopic portfolio: Acessa and Bolder • 10.6% constant currency organic Surgical re
Slide 25: Strong Balance Sheet for Future Capital Deployment Opportunities
Strong Balance Sheet for Future Capital Deployment Opportunities • Leverage well under 1x provides Net Debt and Leverage Ratio* $4.0 firepower for internal investment, M&A, $4.0 $3.5 share repurchases 4.6x $3.1 $3.0 4.0x $2.8 $2.8 ○ Q4’23 leverage of 0.1x $2.6 $2.5 3.3x 2.8x $2.3 2.7x 2.6x $1.9 • No
Slide 26: Presentation Outline
Presentation Outline Introduction Purpose Driven Results Driven Conclusion and Financials 26
Slide 27: Investment Thesis
Investment Thesis • Purpose Driven, Results Driven • Commitment to purpose supercharges engagement and amplifies strength • Transformation into a much stronger Company than pre-pandemic ○ More diverse, recurring revenue ○ More long-term growth opportunities ○ More global ○ With stronger base busines
Slide 28: Financial Overview Q4'23
Financial Overview Q4’23 Non-GAAP $M, except EPS Q4’23 ∆ vs. Q4’22 Revenue $945.3 (0.8%) and (1.5%) CC Organic $936.0 (1.0%) and (1.6%) CC Organic ex COVID $890.3 17.5% and 16.7% CC Gross Margin 60.4% (210 bps) Operating Expenses $303.7 (7.9%) Operating Margin 28.3% 40 bps Net Margin 23.2% 140 bps D
Slide 29: 2024 & Q1'24 Financial Guidance
2024 & Q1’24 Financial Guidance Full Year* Q1’24* 2024 Guidance Q1’24 Guidance Revenue $3,920 – $4,020 $960 – $985 GAAP Diluted EPS $3.19 – $3.39 $0.74 – $0.79 Non-GAAP Diluted EPS $3.90 – $4.10 $0.92 – $0.97 • Expect fiscal 2024 organic revenue ex. COVID growth at the midpoint to be within our long
Slide 30: Appendix
Appendix HOLOGIC' |
Slide 31: COVID Assay and COVID Related Revenue
COVID Assay and COVID Related Revenue COVID Assay and COVID Related Revenue* $823 $800 $78 $760 $700 $664 $80 $661 $63 $596 $77 $600 $514 $73 $500 $71 $400 $365 $745 $352 $41 $680 $61 $300 $601 $584 $523 $215 $443 $187 $163 $200 $42 $324 $36 $98 $291 $36 $100 $173 $27 $55 $45 $27 $151 $127 $23 $71 $
Slide 32: Capitalization as of Q4'23
Capitalization as of Q4’23 Tranche Amount Leverage Coupon Rating Call Date Maturity Cash & Equivalents 2,723 Revolving Facility $2B - SOFR + 110 Baa3 / BBB- 09/25/26 Term Loan 1,485 SOFR + 110 Baa3 / BBB- 09/25/26 Total Secured Debt 1,485 1.1x Senior Unsecured Notes - 2028 400 4.625% Ba2 / BB+ 02/01
Slide 33: Reconciliation of GAAP to Non-GAAP (unaudited)
Reconciliation of GAAP to Non-GAAP (unaudited) $s in millions, except earnings per share Three Months Ended September 30, 2023 September 24, 2022 GROSS PROFIT GAAP gross profit $500.3 $514.6 Adjustments: Amortization of acquired intangible assets 46.4 72.6 Product line discontinuance 24.7 - Impairme
Slide 34: Reconciliation of GAAP to Non-GAAP (unaudited)
Reconciliation of GAAP to Non-GAAP (unaudited) $s in millions, except earnings per share Three Months Ended September 30, 2023 September 24, 2022 OPERATING MARGIN GAAP income from operations $132.5 $140.9 Adjustments to gross profit as detailed above 71.1 81.0 Adjustments to operating expenses as de
Slide 35: Reconciliation of GAAP to Non-GAAP EPS Guidance
Reconciliation of GAAP to Non-GAAP EPS Guidance Guidance Range Quarter Ending December 30, 2023 Year Ending September 28, 2024 Low High Low High GAAP Net Income Per Share $0.74 $0.79 $3.19 $3.39 Amortization of acquired intangible assets $0.21 $0.21 $0.85 $0.85 Restructuring, Integration and Other c
Slide 36: Definitions
Definitions • Organic Revenue: Total constant currency revenue excluding the divested Blood Screening business and revenue from acquired businesses owned by Hologic for less than one year. In fiscal 2024, organic revenue excludes the divested SSI ultrasound imaging business. Revenue from acquired bu
Slide 37: For More Information: Investor Relations
For More Information: Ryan Simon Francis Pruell VP, Investor Relations Senior Director, Investor Relations [email protected] [email protected] 37